Cencora’s Post

New Ask the Expert! In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses factors to be considered in constructing a new facility for cell and gene therapy production as well as using an existing facility to expand cell and gene therapy pipelines. https://lnkd.in/e_pvFpxi

New Ask the Expert! In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses factors to be considered in constructing a new facility for cell and gene therapy production as well as using an existing facility to expand cell and gene therapy pipelines. https://lnkd.in/e_pvFpxi

How do we meet the scale-up challenge in #cellandgenetherapy? This recent article from Mewburn Ellis discusses how future planning and early-adoption of automated manufacture into cell and gene therapy pipelines can set your company up for long-term success. ➡ https://bit.ly/4bcaK6E 

New Ask the Expert! In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses factors to be considered in constructing a new facility for cell and gene therapy production as well as using an existing facility to expand cell and gene therapy pipelines. https://lnkd.in/e_pvFpxi

Cell and gene therapies require specialised logistics services that are able to adequately mitigate cold chain risks. Read our latest blog on the challenges of cell and gene logistics and some of the key considerations developers and manufacturers should be aware of. 👇 https://lnkd.in/gDUuc35P #coldchainlogistics #cellandgenetherapy #cellandgenelogistics

Gene therapy developers, are you in the process of selecting a CDMO? If so, make sure to demand a pilot study for success. Our upcoming online training on Strategic Marketing for the CDMO Industry will explore the crucial reasons why. Don't miss this opportunity to gain valuable insights and elevate your decision-making process. Join us and learn how to select the right CDMO for your gene therapy development. #CDMOSelection #StrategicMarketing #OnlineTraining #SymmetricTraining #pharma

Cell & Gene therapies pose probably the most complex temperature supply chain challenges in life science product development and solution delivery. #Orcaconnect and #Orcacloud provide an integrated, regulatory compliant & high performance temperature management and monitoring solution for C&G shipments available globally. Get in touch if you need our assistance. #cellandgene #connectedsupplychain #temperaturemonitoring #cloudbasedsolutions

Breaking News: Cell and Gene Therapy Emerges as the Pinnacle Trend in Pharma for 2024! Healthcare industry professionals have spoken, rating cell and gene therapy as the leading trend. Dive into the insights with data and analytics from GlobalData. Read more on this groundbreaking development in biopharma: https://lnkd.in/gayTpw4d. 💫

Excellent overview piece on current CGT trends. Real-time precision PAT analytics are a vital component in ensuring treatment effectiveness and success, from the accurate measurement of cellular fitness and characterization of donor/starting materials, to the measurement of potency throughout the manufacturing process. Novel precision analytics such as LumaCyte Laser Force Cytology adds additional benefits in easing the challenges around comparability, a very challenging piece of the puzzle. Developers who are considering commercial reimbursement contracts tied to patient treatment success must do everything they can to ensure their product is manufactured at the highest level of effectiveness and consistency. The constant release of draft guidance and now final guidance from the FDA focused on advanced therapy manufacturing and potency marks a turning point for our industry to break through status quo processes and invest in advanced analytics and solutions. The demand ahead for these life changing products is high and to meet this need we all must be laser focused on innovation and investing now in novel technologies and next generation analytics and processes that will ensure these treatments are manufactured at consistent and effective scale.

Cell Therapy Industry Looks for Ways to Sustain Growth Cell manufacturing trends should encourage optimism. The number of approved cell and gene therapies is bound to rise from today’s total, which is about 30 in the United States, because thousands of cell and gene therapy candidates are being evaluated in clinical pipelines. Besides contributing to the clinical success of cell and gene therapies, cell manufacturing represents an expanding market. According to Vantage Market Research, the global cell and gene therapy manufacturing market should maintain an annual growth rate of 18.2% through the rest of the decade, attaining a value of $15.4 billion by 2030. https://ow.ly/nJuL50QmbgQ